Suppr超能文献

使用聚合的C9制备针对人末端补体复合物新抗原的单克隆抗体。

Using polymerized C9 to produce a monoclonal antibody against a neoantigen of the human terminal complement complex.

作者信息

Kusunoki Y, Takekoshi Y, Nagasawa S

机构信息

Department of Pediatrics, School of Medicine, Hokkaido University, Japan.

出版信息

J Pharmacobiodyn. 1990 Jul;13(7):454-60. doi: 10.1248/bpb1978.13.454.

Abstract

The terminal complement complex (TCC), consisting of C5b, C6, C7, C8, and C9, contains neoantigens that are absent from the individual native components. Neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. The present study describes production of monoclonal antibodies (MoAbs) against neoantigens of both forms of the TCC using human C9 polymerized in Zn2+ as an immunogen. One of ten MoAbs obtained, MoAb 1B4, reacted with the tubular C9 polymer, but not with either the native or sodium dodecyl sulfate-denatured monomeric C9, as shown by enzyme-linked immunosorbent assay and Western blotting. Moreover, MoAb 1B4 cross-reacted both with MAC and SC5b-9. This suggests MoAb 1B4 recognized a neoantigen in the moiety of C9 polymer in the TCC. MoAb 1B4 will be of value for definitive identification of MAC and for quantitation of SC5b-9 in plasma and urine.

摘要

末端补体复合物(TCC)由C5b、C6、C7、C8和C9组成,含有单个天然成分中不存在的新抗原。新抗原存在于膜结合(MAC)和液相(SC5b-9)复合物中。本研究描述了以在Zn2+中聚合的人C9作为免疫原,生产针对两种形式TCC新抗原的单克隆抗体(MoAb)。通过酶联免疫吸附测定和蛋白质印迹法显示,所获得的十种MoAb之一,即MoAb 1B4,与管状C9聚合物反应,但不与天然或十二烷基硫酸钠变性的单体C9反应。此外,MoAb 1B4与MAC和SC5b-9均发生交叉反应。这表明MoAb 1B4识别了TCC中C9聚合物部分的一种新抗原。MoAb 1B4对于MAC的明确鉴定以及血浆和尿液中SC5b-9的定量将具有重要价值。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验